Literature DB >> 31141053

Effect of artemisinin-piperaquine treatment on the electrocardiogram of malaria patients.

Wanting Wu1, Yuan Liang1, Guangchao Wu1, Yinghang Su1, Hongying Zhang1, Zhenyan Zhang1, Changsheng Deng1,2, Qi Wang1, Bo Huang1,2, Bo Tan2, Chongjun Zhou2, Jianping Song1,2.   

Abstract

INTRODUCTION: Concern regarding the cardiotoxicity of antimalarials has been renewed because of their potential to cause QT/QTc interval prolongation related to torsade de pointes (TdP). Artemisinin-piperaquine (AP) is considered an effective artemisinin-based combination therapy (ACT) for malaria.
METHODS: This study involved a retrospective analysis of clinical data of 93 hospitalized malaria patients who had received AP orally. Electrocardiograms (ECGs) were obtained at specific time points in the original study.
RESULTS: Some cases of QT prolongation were observed. However, no TdP was found.
CONCLUSIONS: AP may cause QT interval prolongation in some malaria patients but may not lead to TdP.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31141053     DOI: 10.1590/0037-8682-0453-2018

Source DB:  PubMed          Journal:  Rev Soc Bras Med Trop        ISSN: 0037-8682            Impact factor:   1.581


  3 in total

1.  Electrocardiographic safety evaluation of extended artemether-lumefantrine treatment in patients with uncomplicated Plasmodium falciparum malaria in Bagamoyo District, Tanzania.

Authors:  Lwidiko E Mhamilawa; Sven Wikström; Bruno P Mmbando; Billy Ngasala; Andreas Mårtensson
Journal:  Malar J       Date:  2020-07-14       Impact factor: 2.979

2.  Electrocardiographic effect of artemisinin-piperaquine, dihydroartemisinin-piperaquine, and artemether-lumefantrine treatment in falciparum malaria patients.

Authors:  Wanting Wu; Chenguang Lu; Yuan Liang; Hongying Zhang; Changsheng Deng; Qi Wang; Qin Xu; Bo Tan; Chongjun Zhou; Jianping Song
Journal:  Rev Soc Bras Med Trop       Date:  2021-02-10       Impact factor: 1.581

3.  Safety and efficacy of artemisinin-piperaquine for treatment of COVID-19: an open-label, non-randomised and controlled trial.

Authors:  Guoming Li; Mei Yuan; Haihong Li; Changsheng Deng; Qi Wang; Yexiao Tang; Hongying Zhang; Weisheng Yu; Qin Xu; Yuanyuan Zou; Yueming Yuan; Jiawen Guo; Chunming Jin; Xiangdong Guan; Fengjie Xie; Jianping Song
Journal:  Int J Antimicrob Agents       Date:  2020-11-02       Impact factor: 5.283

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.